Keyphrases
Hybridoma
100%
Functional Activity
100%
ScFv
100%
ScFv Antibody
100%
Human Vascular Endothelial Growth Factor
100%
Vascular Endothelial Growth Factor
66%
Monoclonal Antibody
66%
Age-related Macular Degeneration
66%
Cells in Culture
33%
Clinical Application
33%
Diabetic Retinopathy
33%
Therapeutic Target
33%
Neovascularization
33%
Topical Treatment
33%
Human Umbilical Vein Endothelial Cells (HUVECs)
33%
Eye Diseases
33%
Ocular Surface
33%
Less Invasive
33%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
33%
Ocular Diseases
33%
Single-chain Antibody Fragment
33%
Intraocular Injection
33%
Neovascular Disease
33%
Medicine and Dentistry
Vasculotropin
100%
Hybridoma
100%
Single Chain Fragment Variable Antibody
100%
Disease
40%
Monoclonal Antibody
40%
Age Related Macular Degeneration
40%
Eye Disease
20%
Diabetic Retinopathy
20%
Topical Treatment
20%
Ocular Surface
20%
Human Umbilical Vein Endothelial Cell
20%
Intraocular Drug Administration
20%
Immunology and Microbiology
Vasculotropin
100%
Hybridoma
100%
Single-Chain Variable Fragment
100%
Monoclonal Antibody
40%
Surface Property
20%
Umbilical Vein Endothelial Cell
20%
Neovascularization (Pathology)
20%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
100%
Single Chain Fragment Variable Antibody
100%
Disease
40%
Monoclonal Antibody
40%
Age Related Macular Degeneration
40%
Diabetic Retinopathy
20%
Eye Disease
20%
Neovascularization (Pathology)
20%
Neuroscience
Vascular Endothelial Growth Factor
100%
Single-Chain Variable Fragment
100%
Monoclonal Antibody
40%
Age-Related Macular Degeneration
40%
Diabetic Retinopathy
20%
Ophthalmic Disorder
20%
Human Umbilical Vein Endothelial Cell
20%